3D Printed Breast implants consisting of 200cc in
volume of CollPlant's rhCollagen-based bioinks produced on a
Stratasys' Origin® printer to be tested
Technology innovation addresses a $3.0
billion market opportunity
Study to focus on ability of implants to grow natural breast
tissue and completely degrade over time
REHOVOT, Israel & EDEN
PRAIRIE, Minn., Aug. 19,
2024 /PRNewswire/ -- In a significant step in the
advancement of regenerative medicine, CollPlant Biotechnologies
(Nasdaq: CLGN) and Stratasys Ltd. (Nasdaq: SSYS) today announced
the initiation of a pre-clinical study with 200cc commercial-sized
regenerative implants printed on a Stratasys Origin® 3D
printer.
The collaboration between CollPlant and Stratasys is
currently focused on the development of a bioprinting solution for
CollPlant's breast implants, in addition to finding solutions to
scale-up the implant's fabrication process. The study is intended
to test the ability of the implants to promote the growth of
natural breast tissue and completely degrade over time.
CollPlant's novel breast implants have been designed to
regenerate an individual's natural breast tissue without eliciting
an immune response, and could provide a revolutionary alternative
for both reconstructive and aesthetic procedures, which represents
a significant portion of the overall $3
billion addressable breast implant market.
"This pre-clinical study marks a significant step forward in our
effort to provide patients with care using regenerative medicine
instead of traditional implants," said Stratasys CEO Dr.
Yoav Zeif. "CollPlant's work is
truly inspiring, and our collaboration exemplifies how Stratasys
partners with customers to push the timeline and the boundaries of
innovation. Together, we are driven by a shared mission to
challenge the status quo and find new ways to improve lives and
advance healthcare."
Yehiel Tal, CEO of CollPlant,
commented, "We are extremely happy about the progress we've made
with our breast implants program, and with Stratasys' successful
achievement to develop a printer that enables us to print a
commercial-size implant with high resolution and optimal physical
properties. The combined pioneering technologies of both companies
is expected to streamline the development and production process so
that we have the most efficient means to produce our regenerative
breast implants. We believe that our rhCollagen-based regenerative
implant has the potential to overcome the challenges of existing
breast procedures that use silicone implants or autologous fat
transfer, thereby significantly improving patient
outcomes."
Stratasys is a leader in polymer 3D printing solutions and
CollPlant is a pioneering regenerative and aesthetics medicine
company developing innovative technologies and products based on
its rhCollagen for tissue regeneration and organ manufacturing.
Since announcing the collaboration in April of 2023, Stratasys
has adapted the Origin printer to print the regenerative implants,
and CollPlant successfully managed to 3D-print them at 200ccs.
CollPlant is expecting to have initial results from the study in
the first half of 2025.
Currently the global breast implant market is estimated to be
$3.0 billion,1 while
breast reconstruction and augmentation procedures represent the
second most common plastic surgery procedure performed
worldwide2. The most common breast augmentation or
reconstruction procedures utilize synthetic breast implantations
made of silicone, an artificial substitution for natural
regenerated tissue with a risk of complications.
Earlier this year, CollPlant announced additional positive data
from its previous pre-clinical studies that are currently underway
which showed evidence of well-developed connective tissue
containing blood vessels (i.e., neovascularization) within the
implant. Progressing tissue ingrowth inside the implant was also
observed confirming tissue regeneration. An initial biodegradation
process was noticed, while the original structure of the 3D breast
implant was preserved. No adverse tissue reaction was present,
confirming the safety profile of this novel implant in
development.
1 https://www.thebrainyinsights.com/report/breast-implants-market-14142
2 ISAPS International Survey on
Aesthetic/Cosmetic Procedures, 2021
About Stratasys
Stratasys is leading the global shift to additive manufacturing
with innovative 3D printing solutions for industries such as
aerospace, automotive, consumer products, healthcare, fashion and
education. Through smart and connected 3D printers, polymer
materials, a software ecosystem, and parts on demand, Stratasys
solutions deliver competitive advantages at every stage in the
product value chain. The world's leading organizations turn to
Stratasys to transform product design, bring agility to
manufacturing and supply chains, and improve patient care.
To learn more about Stratasys, visit www.stratasys.com, the
Stratasys blog, X/Twitter, LinkedIn, or Facebook. Stratasys
reserves the right to utilize any of the foregoing social media
platforms, including the Company's websites, to share material,
non-public information pursuant to the SEC's Regulation FD. To the
extent necessary and mandated by applicable law, Stratasys will
also include such information in its public disclosure filings.
Stratasys and Origin One are trademarks or registered trademarks
and the Stratasys signet is a trademark of Stratasys Ltd. and/or
its subsidiaries or affiliates. All other trademarks are the
property of their respective owners.
About CollPlant
CollPlant is a regenerative and aesthetic medicine company
focused on 3D bioprinting of tissues and organs, and medical
aesthetics. CollPlant's products are based on its recombinant human
collagen produced with its proprietary plant based genetic
engineering technology. These products address indications for the
diverse fields of tissue repair, aesthetics, and organ
manufacturing, and are ushering in a new era in regenerative and
aesthetic medicine.
In 2021 CollPlant entered into a development and global
commercialization agreement for dermal and soft tissue fillers with
Allergan, an AbbVie company, the global leader in the dermal filler
market.
For more information, visit http://www.collplant.com
Safe Harbor for Forward-Looking Statements
This joint press release may include forward-looking statements.
Forward-looking statements may include, but are not limited to,
statements relating to Stratasys' and/or CollPlant's objectives,
plans and strategies, as well as statements, other than historical
facts, that address activities, events or developments that
Stratasys and/or CollPlant intend, expect, project, believe or
anticipate will or may occur in the future. These statements are
often characterized by terminology such as "believes," "hopes,"
"may," "anticipates," "should," "intends," "plans," "will,"
"expects," "estimates," "projects," "positioned," "strategy" and
similar expressions and are based on assumptions and assessments
made in light of the companies' respective management's experience
and perception of historical trends, current conditions, expected
future developments and other factors believed to be appropriate.
Forward-looking statements included in this press release include,
but are not limited to, statements regarding the following: the
companies' ability to develop a 3D bioprinter that is based on
Stratasys' P3™ 3D printing technology and can be used
with CollPlant's rhCollagen-based BioInk; CollPlant's expectations
regarding the cost and timing of commencing or concluding
pre-clinical and clinical trials, with respect to breast implants,
tissues and organs based on its rhCollagen based bioinks and
other products for medical aesthetics; CollPlant's ability to
obtain favorable pre-clinical and clinical trial results with
respect to the foregoing trials; regulatory action with respect to
rhCollagen based bioinks and medical aesthetics products including
but not limited to acceptance of an application for marketing
authorization review and approval of such application, and, if
approved, the scope of the approved indication and labeling;
commercial success and market acceptance of the companies' combined
3D bioprinter and/or future potential collaborative products
involving Stratasys' P3™ 3D printing technology and/or
CollPlant's rhCollagen based bioinks and/or CollPlant's
regenerative breast implants and/or other medical aesthetics
products; the companies' ability to establish sales and marketing
capabilities or enter into agreements with third parties, including
third party distributors and resellers; and the companies' ability
to establish and maintain strategic partnerships and other
corporate collaborations. Forward-looking statements are not
guarantees of future performance and are subject to risks and
uncertainties that could cause actual results to differ materially
from those expressed or implied in such statements. Many factors
could cause Stratasys' or CollPlant's actual activities or results
to differ materially from the activities and results anticipated in
forward-looking statements, including, but not limited to, the
following: CollPlant's history of significant losses, its ability
to continue as a going concern, and its need to raise additional
capital and its inability to obtain additional capital on
acceptable terms, or at all; the companies' reliance on third
parties to conduct some or all aspects of the development or
manufacturing of their products; the scope of protection the
companies are able to establish and maintain for their respective
and joint intellectual property rights and the companies' ability
to operate their respective businesses and their joint
collaboration without infringing the intellectual property rights
of others; the overall global economic environment; the impact of
competition and new technologies; general market, political, and
economic conditions in the countries in which the companies
operate, including, with respect to the ongoing war in Israel; projected capital expenditures and
liquidity; changes in the companies' respective strategies; and
litigation and regulatory proceedings. More detailed information
about the risks and uncertainties affecting Stratasys and CollPlant
are contained under the heading "Risk Factors" included in Item 3.D
of their most recent annual reports on Form 20-F filed with the SEC
on March 3, 2023 and March 29, 2023, respectively, and in other
filings that Stratasys and CollPlant have made and may make with
the SEC in the future. The forward-looking statements contained in
this press release are made as of the date of this press release
and reflect Stratasys' and CollPlant's current views with respect
to future events, and the companies do not undertake and
specifically disclaim any obligation to update or revise any
forward-looking statements, whether as a result of new information,
future events or otherwise.
Photo
-https://mma.prnewswire.com/media/2484562/CollPlant_Stratasys_Origin.jpg
Logo -
https://mma.prnewswire.com/media/2217353/CollPlant_Logo.jpg
Contacts:
Media:
Erik Snider, Stratasys Corporate,
Global Public Relations
+972 74 745 6053
Chris Reese, Stratasys Corporate,
Americas Public Relations
+1 651 357 0877
Investor Relations:
Yonah Lloyd, CCO & VP Investor
Relations
+972 74 745 4919
CollPlant
Eran Rotem, Deputy CEO &
CFO
Eran@CollPlant.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/collplant-and-stratasys-announce-pre-clinical-study-for-regenerative-commercial-sized-breast-implants-302225181.html
SOURCE CollPlant